HF Advisory Group LLC Has $1.61 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

HF Advisory Group LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,975 shares of the medical research company’s stock after acquiring an additional 505 shares during the quarter. HF Advisory Group LLC’s holdings in IQVIA were worth $1,614,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Alliancebernstein L.P. boosted its holdings in shares of IQVIA by 19.1% in the 2nd quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock valued at $1,335,754,000 after buying an additional 952,850 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of IQVIA by 2.2% in the 1st quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock valued at $754,864,000 after buying an additional 81,501 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of IQVIA by 2.9% in the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock valued at $568,460,000 after buying an additional 80,189 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of IQVIA by 3.4% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after buying an additional 77,422 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of IQVIA by 1,852.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,066,764 shares of the medical research company’s stock valued at $423,466,000 after buying an additional 1,960,914 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV traded up $1.84 during mid-day trading on Thursday, reaching $229.09. The company had a trading volume of 101,315 shares, compared to its average volume of 961,451. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The firm has a market cap of $41.58 billion, a price-to-earnings ratio of 31.17, a PEG ratio of 2.22 and a beta of 1.50. The business’s 50-day simple moving average is $244.41 and its 200 day simple moving average is $221.37.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the business earned $2.54 earnings per share. On average, research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IQV. Evercore ISI increased their price target on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research note on Thursday, February 15th. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Truist Financial increased their price target on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Finally, BTIG Research began coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

Insider Activity at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock valued at $10,331,003 over the last ninety days. 1.60% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.